CinCor Pharma, Inc. CINC 深 沪
等待开盘 07-06 09:30:00 美东时间
29.06
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 29.06
- 总市值 127.24万
- 52周最高 43.15
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.53
- 委 比 0.00%
- 总股本 4.38万
- 历史最高 43.15
- 量 比 0
- 振 幅 0.00%
- 历史最低 10.53
- 每 手 1
- 风险率 0.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多产业新闻 | 治疗高血压，阿斯利康“first-in-class”小分子获FDA批准
阿斯利康（AstraZeneca）公司今日宣布，“first-in-class”醛固酮合酶抑制剂Baxfendy（baxdrostat）已获得美国FDA批准，与...
05-19 07:32
AstraZeneca's blood pressure drug wins U.S. approval
AstraZeneca's blood pressure drug wins U.S. approval Baxfendy works by blocking aldosterone, targeting hormonal causes of high blood pressure Drug is also being tested for chronic kidney disease and heart failure AstraZeneca expects it will bring in more than $5 billion in peak annual sales By Bhanv
05-18 14:00
Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer
Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates
04-02 20:11
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.
03-12 18:46
AstraZeneca completes acquisition of CinCor Pharma
AstraZeneca has completed the acquisition of CinCor Pharma, Inc., expanding its portfolio in cardiovascular, renal, and metabolism (CVRM) diseases. Through this transaction, AstraZeneca adds baxdrosta...
2025-11-10 10:09
AstraZeneca succeeds in late-stage trial for blood pressure therapy
AstraZeneca (NASDAQ:AZN) announced on Tuesday that a blood pressure therapy it acquired through its 2023 acquisition of CinCor Pharma has reached its primary goal in a Phase 3 trial, offering new hope...
2025-10-07 19:47
UPDATE 3-AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial
Baxdrostat significantly lowers blood pressure in trial Drug also being tested for kidney disease, heart failure Mechanism of action differs from older hypertension treatments Company targets $80 bill...
2025-10-07 14:23
AstraZeneca is said to seek approval for antihypertensive this year
AstraZeneca (NASDAQ:AZN) plans to submit regulatory filings for its blood pressure treatment baxdrostat by the end of this year, seeking approval for the small molecule therapy potentially in 2026, Re...
2025-08-31 00:03
